{"title":"Head-to-head trial of HCV treatment regimens","authors":"Jordan Hindson","doi":"10.1038/s41575-025-01091-7","DOIUrl":null,"url":null,"abstract":"<p>A head-to-head trial published in <i>The Lancet</i> has compared two antiviral combination regimens for treatment of chronic hepatitis C virus (HCV) infection. The randomized controlled non-inferiority trial (ISRCTN, 61522291), conducted in two public hospitals in Vietnam, randomized adults (<i>n</i> = 624) with chronic HCV infection to receive 400 mg sofosbuvir and either 60 mg daclatasvir or 100 mg velpatasvir.</p><p>The primary outcome of sustained virological response occurred in 294 (97%) participants in the group receiving sofosbuvir and daclatasvir and 292 (95%) participants in the group receiving sofosbuvir and velpatasvir (risk difference 2.2%; 90% credible interval –0.2–4.8; within 5% non-inferiority margin). Therefore, sofosbuvir and daclatasvir was non-inferior to sofosbuvir and velpatasvir. Participants were also randomized to several different novel treatment strategies, which could help expand access to treatment.</p>","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"102 1","pages":""},"PeriodicalIF":45.9000,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Gastroenterology &Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41575-025-01091-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
A head-to-head trial published in The Lancet has compared two antiviral combination regimens for treatment of chronic hepatitis C virus (HCV) infection. The randomized controlled non-inferiority trial (ISRCTN, 61522291), conducted in two public hospitals in Vietnam, randomized adults (n = 624) with chronic HCV infection to receive 400 mg sofosbuvir and either 60 mg daclatasvir or 100 mg velpatasvir.
The primary outcome of sustained virological response occurred in 294 (97%) participants in the group receiving sofosbuvir and daclatasvir and 292 (95%) participants in the group receiving sofosbuvir and velpatasvir (risk difference 2.2%; 90% credible interval –0.2–4.8; within 5% non-inferiority margin). Therefore, sofosbuvir and daclatasvir was non-inferior to sofosbuvir and velpatasvir. Participants were also randomized to several different novel treatment strategies, which could help expand access to treatment.
期刊介绍：
Nature Reviews Gastroenterology & Hepatology aims to serve as the leading resource for Reviews and commentaries within the scientific and medical communities it caters to. The journal strives to maintain authority, accessibility, and clarity in its published articles, which are complemented by easily understandable figures, tables, and other display items. Dedicated to providing exceptional service to authors, referees, and readers, the editorial team works diligently to maximize the usefulness and impact of each publication.
The journal encompasses a wide range of content types, including Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements, all pertinent to gastroenterologists and hepatologists. With its broad scope, Nature Reviews Gastroenterology & Hepatology ensures that its articles reach a diverse audience, aiming for the widest possible dissemination of valuable information.
Nature Reviews Gastroenterology & Hepatology is part of the Nature Reviews portfolio of journals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
